LONDON (Reuters) – A global diabetes epidemic is fuelling record demand for insulin but tens of millions will not get the injections they need unless there is a dramatic improvement in access and affordability, a new study concluded on Wednesday.
FILE PHOTO: An employee poses at the insulin production plant of Danish multinational pharmaceutical company Novo Nordisk in Chartres, north-central France, April 21, 2016. REUTERS/Guillaume Souvant/Pool/File Photo
Diabetes — which can lead to blindness, kidney failure, heart problems, neuropathic pain and amputations — now affects 9 percent of all adults worldwide, up from 5 percent in 1980.
The vast majority have type 2 diabetes, the kind linked to obesity and lack of exercise, and cases are spreading particularly rapidly in the developing world as people adopt more Western, urban lifestyles.
Researchers said the amount of insulin needed to effectively treat type 2 diabetes would rise by more than 20 percent over the next 12 years, but insulin would be beyond the reach of half the 79 million type 2 diabetics predicted to need it in 2030.
vCard.red is a free platform for creating a mobile-friendly digital business cards. You can easily create a vCard and generate a QR code for it, allowing others to scan and save your contact details instantly.
The platform allows you to display contact information, social media links, services, and products all in one shareable link. Optional features include appointment scheduling, WhatsApp-based storefronts, media galleries, and custom design options.
The shortfall is most acute in Africa, where the team led by Dr Sanjay Basu from Stanford University estimated supply would have to rise sevenfold to treat at-risk patients who had reached the stage of requiring insulin to control their blood sugar.
“These estimates suggest that current levels of insulin access are highly inadequate compared to projected need, particularly in Africa and Asia,” Basu said.
“Despite the U.N.’s commitment to treat non-communicable diseases and ensure universal access to drugs for diabetes, across much of the world insulin is scarce and unnecessarily difficult for patients to access.”
Global insulin supply is dominated by three companies — Novo Nordisk, Sanofi and Eli Lilly — which have various programs to try to improve access to their products.
Insulin, however, remains costly and prices can be especially out of reach in poorer countries where tortuous supply chains and high mark-ups by middlemen often make it unaffordable for many patients.
Overall, Basu and colleagues calculated that global insulin use was set to rise to 634 million 1,000-unit vials by 2030 from 526 million in 2018.
Their study, published in the Lancet Diabetes & Endocrinology journal and funded by the Helmsley Charitable Trust, was based on projections of diabetes prevalence from the International Diabetes Federation.
Dr Hertzel Gerstein from Canada’s McMaster University wrote in an accompanying commentary that it was important to estimate and ensure insulin supplies, but added the forecasts should be treated cautiously as they were based on mathematical models.
Reporting by Ben Hirschler; Editing by Adrian Croft